BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 16618770)

  • 1. Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain.
    Kawakami K; Terabe M; Kawakami M; Berzofsky JA; Puri RK
    Cancer Res; 2006 Apr; 66(8):4434-42. PubMed ID: 16618770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
    Eguchi J; Hatano M; Nishimura F; Zhu X; Dusak JE; Sato H; Pollack IF; Storkus WJ; Okada H
    Cancer Res; 2006 Jun; 66(11):5883-91. PubMed ID: 16740728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved.
    Wu TY; Fleischmann WR
    J Interferon Cytokine Res; 2001 Dec; 21(12):1117-27. PubMed ID: 11798470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.
    Nakashima H; Fujisawa T; Husain SR; Puri RK
    J Transl Med; 2010 Nov; 8():116. PubMed ID: 21067607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.
    Kawakami K; Terabe M; Kioi M; Berzofsky JA; Puri RK
    Clin Cancer Res; 2006 Aug; 12(15):4678-86. PubMed ID: 16899618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent antitumor activity of IL-13 cytotoxin in human pancreatic tumors engineered to express IL-13 receptor alpha2 chain in vivo.
    Kawakami K; Kawakami M; Husain SR; Puri RK
    Gene Ther; 2003 Jul; 10(13):1116-28. PubMed ID: 12808442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor mechanism of recombinant murine interleukin-12 vaccine.
    Yin X; Yan X; Yang Q; Cao H; Liang H
    Cancer Biother Radiopharm; 2010 Jun; 25(3):263-8. PubMed ID: 20578831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.
    Ma HL; Whitters MJ; Konz RF; Senices M; Young DA; Grusby MJ; Collins M; Dunussi-Joannopoulos K
    J Immunol; 2003 Jul; 171(2):608-15. PubMed ID: 12847225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain.
    Okano F; Storkus WJ; Chambers WH; Pollack IF; Okada H
    Clin Cancer Res; 2002 Sep; 8(9):2851-5. PubMed ID: 12231526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor cells secreting IL-13 but not IL-13Ralpha2 fusion protein have reduced tumorigenicity in vivo.
    Ma HL; Whitters MJ; Jacobson BA; Donaldson DD; Collins M; Dunussi-Joannopoulos K
    Int Immunol; 2004 Jul; 16(7):1009-17. PubMed ID: 15184346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta.
    Jia ZC; Zou LY; Ni B; Wan Y; Zhou W; Lv YB; Geng M; Wu YZ
    Cancer Immunol Immunother; 2005 May; 54(5):446-52. PubMed ID: 15750831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination using melanoma cells treated with p19arf and interferon beta gene transfer in a mouse model: a novel combination for cancer immunotherapy.
    Medrano RF; Catani JP; Ribeiro AH; Tomaz SL; Merkel CA; Costanzi-Strauss E; Strauss BE
    Cancer Immunol Immunother; 2016 Apr; 65(4):371-82. PubMed ID: 26887933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
    Oniki S; Nagai H; Horikawa T; Furukawa J; Belladonna ML; Yoshimoto T; Hara I; Nishigori C
    Cancer Res; 2006 Jun; 66(12):6395-404. PubMed ID: 16778218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.